Merge
Merge is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Multicentre, Open-label, Randomised, Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator’s Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children under 12 Years of Age with Hyperkalaemia (EMERALD2)
Sponsor Vifor Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)
Sponsor NewAmsterdam Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase II, multinational, multicentre, double-blind, randomised, active-controlled, 3-way cross-over study to evaluate the therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a versus CHF5993 pMDI 100/6/12.5 µg HFA-134a in subjects with mild to moderate asthma. [TRECONY]
Sponsor Chiesi Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Sponsor Carrick Therapeutics Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Merge?
The 2026-10-09 snapshot links Merge to 6 distinct CTIS trials. Recorded services include Investigator Portal, Patient engagement/retention, patient recruitment, patient recruitment, Patient Recruitment Engagement, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Merge?
The most frequently recorded therapeutic areas are Cardiology, Haematological Malignancies, Metabolic Disorders, Nephrology. Recorded phases include Phase 2, Phase 3, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Merge conducted?
The linked trials record locations in 18 countries, including Spain, France, Poland, Czechia, Hungary. These are trial locations, not confirmed office locations or countries where Merge delivered services.
What can this page tell me about Merge's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Merge. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Merge
- Merge LLC